Supplements for Cancer Survivors: What's Safe, What's Not

Androgen deprivation therapy dramatically reduces testosterone, which has downstream effects across nearly every system. Cardiovascular risk increases significantly — men on long-term ADT have meaningfully higher rates of heart attack, stroke, and metabolic syndrome. Bone density declines, sometimes rapidly — ADT-induced osteoporosis is a real cause of fractures in this population. Fatigue, hot flashes, cognitive changes, and depression are common.

Vitamin D3 at 4000 IU addresses two of these directly. VDR receptors are expressed in prostate tissue, and vitamin D deficiency is nearly universal in men undergoing ADT. More importantly, vitamin D supports bone metabolism — a critical concern when testosterone-driven bone protection is removed. Vitamin D alone isn't sufficient for bone protection during ADT (calcium intake matters, and some men need bisphosphonates), but deficiency makes the problem substantially worse.

Omega-3 at 2g EPA+DHA addresses the cardiovascular gap. ADT accelerates atherosclerotic processes, and omega-3's triglyceride-lowering and anti-inflammatory effects are directly relevant to this specific risk. CoQ10 at 200mg ubiquinol supports cardiac muscle function and is particularly relevant for men who are also on statins.

This section is not nuanced: tongkat ali, fadogia agrestis, shilajit, DHEA, pregnenolone, and any supplement marketed to "boost testosterone naturally" are contraindicated for men on androgen deprivation therapy or with hormone-sensitive cancers.

Tongkat ali raises free testosterone by reducing SHBG and stimulating LH production — exactly what ADT is designed to counteract. Fadogia agrestis increases LH secretion, directly stimulating testicular testosterone production. Shilajit increases testosterone through fulvic acid's effects on mitochondrial function in Leydig cells.

These mechanisms are not harmful in the general men's health context. In the ADT context, they directly antagonize a medical intervention that's keeping cancer suppressed.

The same logic applies more broadly to hormone-sensitive cancers. Discuss any new supplement with your oncologist before starting — this is not overcaution, it's the appropriate standard of care.

Ashwagandha occupies an ambiguous position in cancer survivorship. It does not directly stimulate testosterone production through the LH/HPG pathway — its testosterone association in studies is likely secondary to cortisol reduction. However, it has adaptogenic properties that affect multiple hormonal pathways, and there is limited data on its effects in men with hormone-sensitive cancers.

For men who are post-treatment and confirmed in remission from non-hormone-sensitive cancers, ashwagandha at 600mg PM is reasonable for cortisol management and fatigue reduction. For men on ADT or with active hormone-sensitive cancer treatment, the recommendation is to discuss with your oncologist first. This isn't a blanket prohibition — it's an acknowledgment that the data in this specific population is insufficient to give unqualified clearance.

The conservative approach: if you're on active cancer treatment of any kind, get oncologist sign-off on new supplements before starting.

Methylated B-complex supports the methylation pathway, which is frequently disrupted by chemotherapy and radiation. Methylcobalamin (B12) and methylfolate bypass the MTHFR conversion step that many men struggle with, ensuring these essential cofactors are available in their active forms. Nerve health, DNA repair, and energy metabolism all depend on adequate B-vitamin status. This is a safe, appropriate addition for most cancer survivors.

Magnesium at 400mg PM addresses sleep, muscle function, and cardiac rhythm — all relevant in cancer survivorship. Magnesium is depleted by several chemotherapy agents (particularly platinum-based drugs like cisplatin), making deficiency more common in this population. Magnesium glycinate is well-tolerated and doesn't interact with common cancer medications.

Together, methylated B-complex and magnesium address nutritional gaps that are particularly common in men post-treatment, without any hormonal mechanism that would conflict with ongoing cancer management.